
CLAIMS


What is claimed is:

5 1. A compound represented by the following Structural Formula:



and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein:

(a) T1 is selected from the group consisting of



- (b) R1 is selected from the group consisting of hydrogen, C₁-C₈ alkyl,

 C₁-C₈ alkenyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl
 C₀₋₄-alkyl, and C₃-C₆ cycloalkylaryl-C₀₋₂-alkyl, wherein C₁-C₈

 alkyl, C₁-C₈ alkenyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl,

 heteroaryl-C₀₋₄-alkyl, and C₃-C₆ cycloalkylaryl-C₀₋₂-alkyl are each

 optionally substituted with from one to three substituents

 independently selected from R1';
 - (c) R1', R26, R27, R28, R31, Z14', and Z15' are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C₁-C₆ alkyl, C₁-C₆ alkyl-COOR12, C₁-C₆ alkoxy,

10

20

25

30

 C_1 - C_6 haloalkyl, C_1 - C_6 haloalkyloxy, C_3 - C_7 cycloalkyl, optionally substituted aryloxy, optionally substituted aryl- C_{0-4} -alkyl, optionally substituted heterocycloalkyl, C(O)R13, COOR14, OC(O)R15, $OS(O)_2R16$, $N(R17)_2$, NR18C(O)R19, $NR20SO_2R21$, SR22, S(O)R23, $S(O)_2R24$, and $S(O)_2N(R25)_2$; R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24 and R25 are each independently selected from the group consisting of hydrogen, C_1 - C_6 alkyl and aryl;

- (d) R2 is selected from the group consisting of C_0 - C_8 alkyl and C_{1-6} -heteroalkyl;
- (e) X is selected from the group consisting of a bond, O, S, S(O)₂ and N;
- (f) U is an aliphatic linker wherein one carbon atom of the aliphatic linker may be replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with R30;
- 15 (g) Y is selected from the group consisting of C, O, S, NH and a single bond;
 - (h) E is C(R3)(R4)A or A and wherein
 - (i) A is selected from the group consisting of C₀-C₆ alkylcarboxyl, C₀-C₆ alkyltetrazole, C₁-C₆ alkylnitrile, C₀-C₆ alkylcarboxamide, C₀-C₆ alkylsulfonamide and C₀-C₆ alkylacylsulfonamide; wherein C₀-C₆ alkylsulfonamide, C₀-C₆ alkylacylsulfonamide and C₀-C₆ alkyltetrazole are each optionally substituted with from one to two groups independently selected from R⁷;
 - (ii) each R⁷ is independently selected from the group consisting of hydrogen, C₁-C₆ haloalkyl, aryl-C₀-C₄ alkyl and C₁-C₆ alkyl, wherein such alkyl and arylalkyl are each optionally substituted with from one to two groups independently selected from R7'; each R7' is independently selected from halo, C₁-C₆ alkyl, and haloC₁-C₆ alkyl;
 - (iii) R3 is selected from the group consisting of hydrogen, C_1 - C_5 alkyl, and C_1 - C_5 alkoxy; and


:

- (iv) R4 is selected from the group consisting of hydrogen, C₁-C₅ alkyl, C₁-C₅ alkoxy, aryloxy, C₃-C₆ cycloalkyl, and aryl C₀-C₄ alkyl, and R3 and R4 are optionally combined to form a C₃-C₄ cycloalkyl, and wherein alkyl, alkoxy, cycloalkyl and aryl-alkyl are each optionally substituted with one to three each independently selected from R26;
- (i) Z5 is S or O;
- Z12 is selected from the group consisting of hydrogen and -Z13C₀-C₃alkylZ14;
- 10 (k) Z13 is selected from the group consisting of a single bond, CO, CO₂, CONZ15, and SO₂;
 - (l) Z14 is selected from the group consisting of aryl and heteroaryl, wherein the aryl and heteroaryl is each optionally substituted with from one to three substituents independently selected from Z14';
- (m) Z15 is selected from the group consisting of hydrogen aryl and heteroaryl, wherein the aryl and heteroaryl is each optionally substituted with from one to three substituents independently selected from Z15';
 - (n) R9 is selected from the group consisting of hydrogen, C₁-C₄ alkyl, C₁-C₄ alkylenyl, halo, aryl-C₀-C₄ alkyl, heteroaryl, C₁-C₆ allyl, and OR29, and wherein aryl-C₀-C₄ alkyl, heteroaryl are each optionally substituted with from one to three independently selected from R27; R29 is selected from the group consisting of hydrogen and C₁-C₄ alkyl;
- (o) R10, R11 are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C₁-C₆ alkyl, C₀-C₆ alkyl-COOR12", C₁-C₆ alkoxy, C₁-C₆ haloalkyl, C₁-C₆ haloalkyloxy, C₃-C₇ cycloalkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, C3-C6 cycloalkylaryl-C₀₋₂-alkyl, aryloxy, C(O)R13",
 COOR14', OC(O)R15', OS(O)₂R16', N(R17')₂, NR18'C(O)R19', NR20'SO₂R21', SR22', S(O)R23', S(O)₂R24', and S(O)₂N(R25')₂;

10


and wherein aryl- C_{0-4} -alkyl, aryl- C_{1-6} -heteroalkyl, heteroaryl- C_{0-4} -alkyl, and C3-C6 cycloalkylaryl- C_{0-2} -alkyl are each optionally substituted with from one to three independently selected from R28;

- (p) R12', R12", R13', R14', R15', R16', R17', R18', R19', R20', R21',
 R22', R23', R24', and R25' are each independently selected from the group consisting of hydrogen, C₁-C₆ alkyl and aryl;
- (q) R30 is selected from the group consisting of C₁-C₆ alkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C3-C6 cycloalkylaryl-C₀₋₂-alkyl, and wherein C₁-C₆ alkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C3-C6 cycloalkylaryl-C₀₋₂-alkyl are each optionally substituted with from one to three substituents each independently selected from R31;
- (r) R32 is selected from the group consisting of a bond, hydrogen, halo, C₁-C₆ alkyl, C₁-C₆ haloalkyl, and C₁-C₆ alkyloxo;
- 15 (s) R33 is selected from the group consisting of C2-C8 alkyl, C1-C8



alkoxy, phenyl, thiophene, pyridine, piperidine,

, wherein the C2-C8 alkyl, C1-C8



alkoxy, phenyl, thiophene, pyridine, piperidine,

WO 2004/092131 PCT/US2003/041698

, and , are each optionally substituted with R10

and R11; and

(t) provided that when Y is C or a bond, at least one of R1, R2, R3, and R4 is C1-C4 alkyl.

5

2. The compound of Claim 1, wherein A is selected from the group consisting of C₀-C₆ alkylcarboxyl, C₀-C₆ alkyltetrazole, C₁-C₆ alkylnitrile, C₀-C₆ alkylsulfonamide and C₀-C₆ alkylacylsulfonamide; wherein C₀-C₆ alkylsulfonamide, C₀-C₆ alkylacylsulfonamide and C₀-C₆ alkyltetrazole are each optionally substituted with from one to two groups independently selected from R⁷.

10

3. The compound of Claim 1, wherein the compound is represented by the following Structural Formula:

15

and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein:

20

(a) T1 is selected from the group consisting of

- (b) R1 is selected from the group consisting of hydrogen, C₁-C₈ alkyl, C₁-C₈ alkenyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C₃-C₆ cycloalkylaryl-C₀₋₂-alkyl, wherein C₁-C₈ alkyl, C₁-C₈ alkenyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C₃-C₆ cycloalkylaryl-C₀₋₂-alkyl are each optionally substituted with from one to three substituents independently selected from R1';
- (c) R1', R26, R27, R28, R31, Z14', and Z15' are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C₁-C₆ alkyl, C₁-C₆ alkyl-COOR12, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, C₁-C₆ haloalkyloxy, C₃-C₇ cycloalkyl, aryloxy, aryl-C₀-4-alkyl, heteroaryl, heterocycloalkyl, C(O)R13, COOR14, OC(O)R15, OS(O)₂R16, N(R17)₂, NR18C(O)R19, NR20SO₂R21, SR22, S(O)R23, S(O)₂R24, and S(O)₂N(R25)₂; R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24 and R25 are each independently selected from the group consisting of hydrogen, C₁-C₆ alkyl and aryl;
 - (d) R2 is selected from the group consisting of C_0 - C_8 alkyl and C_{1-6} -heteroalkyl;
 - (e) X is selected from the group consisting of a bond, O, S, S(O)₂ and N;
 - (f) U is an aliphatic linker wherein one carbon atom of the aliphatic linker may be replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with R30;
- 25 (g) Y is selected from the group consisting of C, O, S, NH and a single bond;
 - (h) E is C(R3)(R4)A or A and wherein


(i) A is selected from the group consisting of carboxyl, tetrazole, C₁-C₆ alkylnitrile, carboxamide, sulfonamide and acylsulfonamide; wherein sulfonamide, acylsulfonamide and tetrazole are each optionally substituted with from one to two 5 groups independently selected from R7; (ii) each R⁷ is independently selected from the group consisting of hydrogen, C_1 - C_6 haloalkyl, aryl- C_0 - C_4 alkyl and C_1 - C_6 alkyl, wherein such alkyl and arylalkyl are each optionally substituted with from one to two groups independently selected from R7'; each R7' is independently selected from halo, C1-C6 alkyl, and 10 haloC₁-C₆ alkyl; (iii) R3 is selected from the group consisting of hydrogen, C₁-C₅ alkyl, and C1-C5 alkoxy; and (iv) R4 is selected from the group consisting of hydrogen, C₁-C₅ 15 alkyl, C1-C5 alkoxy, aryloxy, C3-C6 cycloalkyl, and aryl C0-C4 alkyl, and R3 and R4 are optionally combined to form a C3-C4 cycloalkyl, and wherein alkyl, alkoxy, cycloalkyl and aryl-alkyl are each optionally substituted with one to three each independently selected from R26; 20 (i) **Z5** is **S** or **O**: Z12 is selected from the group consisting of hydrogen and -Z13C₀-**(j)** C3alkylZ14: Z13 is selected from the group consisting of a single bond, CO, CO₂, (k) CONZ15, and SO₂; Z14 is selected from the group consisting of aryl and heteroaryl, 25 **(1)** wherein the aryl and heteroaryl is each optionally substituted with from one to three substituents independently selected from Z14'; Z15 is selected from the group consisting of hydrogen aryl and (m) heteroaryl, wherein the aryl and heteroaryl is each optionally 30 substituted with from one to three substituents independently selected from Z15';

10


- (n) R9 is selected from the group consisting of hydrogen, C₁-C₄ alkyl, C₁-C₄ alkylenyl, halo, aryl-C₀-C₄ alkyl, heteroaryl, C₁-C₆ allyl, and OR29, and wherein aryl-C₀-C₄ alkyl, heteroaryl are each optionally substituted with from one to three independently selected from R27; R29 is selected from the group consisting of hydrogen and C₁-C₄ alkyl;
- (o) R10, R11 are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C₁-C₆ alkyl, C₀-C₆ alkyl-COOR12", C₁-C₆ alkoxy, C₁-C₆ haloalkyl, C₁-C₆ haloalkyloxy, C₃-C₇ cycloalkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, C3-C6 cycloalkylaryl-C₀₋₂-alkyl, aryloxy, C(O)R13", COOR14", OC(O)R15", OS(O)₂R16", N(R17")₂, NR18"C(O)R19", NR20"SO₂R21", SR22", S(O)R23", S(O)₂R24", and S(O)₂N(R25")₂; and wherein aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C3-C6 cycloalkylaryl-C₀₋₂-alkyl are each optionally substituted with from one to three independently selected from R28;
- (p) R12', R12'', R13', R14', R15', R16', R17', R18', R19', R20', R21',
 R22', R23', R24', and R25' are each independently selected from the group consisting of hydrogen, C₁-C₆ alkyl and aryl;
- 20 (q) R30 is selected from the group consisting of C₁-C₆ alkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C3-C6 cycloalkylaryl-C₀₋₂-alkyl, and wherein C₁-C₆ alkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C3-C6 cycloalkylaryl-C₀₋₂-alkyl are each optionally substituted with from one to three substituents each independently selected from R31;
 - (r) R32 is selected from the group consisting of a bond, hydrogen, halo, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, and C_1 - C_6 alkyloxo;

(s) R33 is selected from the group consisting of phenyl, thiophene,

pyridine, piperidine,




wherein the phenyl, thiophene, pyridine, piperidine,



and R11; and

- (u) provided that when Y is C or a bond, R1, R2, R3, and R4 are each independently C1-C4 alkyl.
- 4. The compound of Claim 2, wherein the compound is represented by the following Structural Formula:



15

5. The compound of Claim 1, wherein the compound is represented by the following Structural Formula:

5 6. The compound of Claim 5, wherein the compound is represented by the following Structural Formula:

7. The compound of Claim 6, wherein the compound is represented by the following Structural Formula:

$$R_{10}$$

- 8. The compound of Claim 7, wherein X is a bond.
- 9. The compound of Claim 7, wherein X is -S-.
- 10. The compound of Claim 7, wherein X is -O-.

25

- 11. The compound of Claim 10 wherein E is -COOH, C₁-C₆ alkylcarboxyl, or C(R3)(R4)-C₁-C₆ alkyl-COOH.
- The compound of Claim 11 wherein R10 and R11 are each independently
 selected from the group consisting of hydrogen, halo, oxo, C₁-C₆ alkyl, C₁-C₆ alkyl-COOR12", C₁-C₆ alkoxy, C₁-C₆ haloalkyl, and C₁-C₆ haloalkyloxy.
 - 13. The compound of Claim 12 wherein R10 is selected from the group consisting of C₃-C₇ cycloalkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, C3-C6 cycloalkylaryl-C₀₋₂-alkyl, and aryloxy.
 - 14. The compound of Claim 13, wherein R10 is CF₃.
- 15. The compound of Claim 11, wherein R9 is selected from the group consisting of hydrogen and C₁-C₃ alkyl.
 - 16. The compound of Claim 15, wherein R1, R3, and R4 are each independently selected from the group consisting of hydrogen and C₁-C₂ alkyl.
- 20 17. The compound of Claim 16 wherein R2 is a bond.
 - 18. The compound of Claim 17, wherein U is: saturated C₁-C₃ alkyl; and optionally substituted with C₁-C₃ alkyl.

19. The compound of Claim 6, wherein the compound is represented by the following Structural Formula:

$$R10$$
 $R9$
 $R1$
 $R1$
 $R2$
 $R10$
 $R11$

- 20. The compound of Claim 19, wherein X is a bond.
- 5 21. The compound of Claim 19, wherein X is -S-.
 - 22. The compound of Claim 19, wherein X is -O-.
- 23. The compound of Claim 22 wherein E is -COOH, C₁-C₆ alkylcarboxyl, or C(R3)(R4)-C₁-C₆ alkyl-COOH.
 - 24. The compound of Claim 23 wherein R10 and R11 are each independently selected from the group consisting of hydrogen, halo, oxo, C₁-C₆ alkyl, C₁-C₆ alkyl-COOR12", C₁-C₆ alkoxy, C₁-C₆ haloalkyl, and C₁-C₆ haloalkyloxy.
 - 25. The compound of Claim 24 wherein R10 is selected from the group consisting of C₃-C₇ cycloalkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, C3-C6 cycloalkylaryl-C₀₋₂-alkyl, and aryloxy.
- 20 26. The compound of Claim 25, wherein R10 is CF₃.
 - 27. The compound of Claim 24, wherein R9 is selected from the group consisting of hydrogen and C₁-C₃ alkyl.
- 25 28. The compound of Claim 27, wherein R1, R3, and R4 are each independently selected from the group consisting of hydrogen and C₁-C₂ alkyl.

WO 2004/092131 PCT/US2003/041698

- 206 -

- 29. The compound of Claim 28 wherein R2 is a bond.
- 30. The compound of Claim 29, wherein U is:

saturated C₁-C₃ alkyl; and

- 5 optionally substituted with C₁-C₃ alkyl.
 - 31. The compound of Claim 6, wherein the compound is represented by the following Structural Formula:

$$R1$$
 $R1$
 $R2$
 $R10$
 $R10$

10

- 32. The compound of Claim 31, wherein X is a bond.
- 33. The compound of Claim 31, wherein X is -S-.
- 15 34. The compound of Claim 31, wherein X is -O-.

(

- 35. The compound of Claim 34 wherein E is -COOH, C₁-C₆ alkylcarboxyl, or C(R3)(R4)-C₁-C₆ alkyl-COOH.
- 20 36. The compound of Claim 35 wherein R10 and R11 are each independently selected from the group consisting of hydrogen, halo, oxo, C₁-C₆ alkyl, C₁-C₆ alkyl-COOR12", C₁-C₆ alkoxy, C₁-C₆ haloalkyl, and C₁-C₆ haloalkyloxy.
- The compound of Claim 36 wherein R10 is selected from the group consisting of C₃-C₇ cycloalkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, C3-C6 cycloalkylaryl-C₀₋₂-alkyl, and aryloxy.
 - 38. The compound of Claim 37, wherein R10 is CF₃.

WO 2004/092131

- 39. The compound of Claim 36, wherein R9 is selected from the group consisting of hydrogen and C₁-C₃ alkyl.
- 5 40. The compound of Claim 39, wherein R1, R3, and R4 are each independently selected from the group consisting of hydrogen and C₁-C₂ alkyl.
 - 41. The compound of Claim 40 wherein R2 is a bond.
- 10 42. The compound of Claim 41, wherein U is: saturated C₁-C₃ alkyl; and optionally substituted with C₁-C₃ alkyl.
- 43. The compound of Claim 1 wherein the compound is selected from the group consisting of:
 - Racemic-(6-{1-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-1H-indol-3-yl)-acetic acid;
 - Racemic-(6-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-propoxy}-1H-indol-3-yl)-acetic acid;
- 20 Racemic-(1-Methyl-6-{2-[5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-propoxy}-1H-indol-3-yl)-acetic acid;
 - (S)-(6-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-propoxy}-1H-indol-3-yl)-acetic acid;
 - (R)-(6-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-propoxy}-1H-indol-3-yl)-acetic acid;
 - Racemic-(6-Hydroxy-5-{1-[4-isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethyl}-1H-indol-3-yl)-acetic acid;
 - (6-{2-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-propoxy}-1-methyl-1H-indol-3-yl)-acetic acid;
- 30 (1-Methyl-6-{2-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-propoxy}-1H-indol-3-yl)-acetic acid;


WO 2004/092131 PCT/US2003/041698

(6-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-propoxy}-1methyl-1H-indol-3-yl)-acetic acid; (R)-(6-{2-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-propoxy}-1-methyl-1H-indol-3-yl)-acetic acid; 5 (S)-(6-{2-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-propoxy}-1-methyl-1H-indol-3-yl)-acetic acid: Racemic-(1-Methyl-6-{2-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5yl]-propoxy}-1H-indol-3-yl)-acetic acid; Racemic-(1-Ethyl-6-{2-[4-isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-10 yl]-propoxy}-1H-indol-3-yl)-acetic acid; Racemic-(6-{2-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]propoxy}-1-propyl-1H-indol-3-yl)-acetic acid; {1-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethyl]-1H-indol-5-yloxy}-acetic acid; 15 Racemic(6-{1-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]ethoxy}-1H-indol-3-yl)-acetic acid: Racemic(6-{1-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-1H-indol-3-yl)-acetic acid; (R)-(6-{1-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-20 1H-indol-3-yl)-acetic acid; (S)-(6-{1-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-1H-indol-3-yl)-acetic acid: (R)-(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-propoxy}-1H-indol-3-yl)-acetic acid; 25 (S)-(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-propoxy}-1H-indol-3-yl)-acetic acid; (5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-1Hindol-3-yl)-acetic acid: (R)-(1-Methyl-5-{2-[5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-30 propoxy}-1H-indol-3-yl)-acetic acid; (S)-(1-Methyl-5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-

propoxy}-1H-indol-3-yl)-acetic acid;


20

- (1-Methyl-5-{2-[5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-1H-indol-3-yl)-acetic acid;
- 5-{2-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-yl]-propoxy}-1H-indole-2-carboxylic acid; and
- 5 5-{2-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-yl]-propoxy}-1-methyl-1H-indole-2-carboxylic acid.
 - 44. The compound of Claim 1, wherein the compound is in the S conformation.
- 10 45. The compound of Claim 1, wherein the compound is in the R conformation.
 - 46. The compound of Claim 1, wherein the compound is radiolabeled.
 - 47. A compound represented by the following Structural Formula:



and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein:

(a) T1 is selected from the group consisting of



R1 is selected from the group consisting of hydrogen, C1-C8 alkyl, (b) C_1 - C_8 alkenyl, aryl- C_{0-4} -alkyl, aryl- C_{1-6} -heteroalkyl, heteroaryl- C_{0-4} -alkyl, and C3-C6 cycloalkylaryl- C_{0-2} -alkyl, wherein C_1 - C_8 alkyl, C_1 - C_8 alkenyl, aryl- C_{0-4} -alkyl, aryl- C_{1-6} -heteroalkyl, 5 heteroaryl- C_{0-4} -alkyl, and C3-C6 cycloalkylaryl- C_{0-2} -alkyl are each optionally substituted with from one to three substituents independently selected from R1'; R1', R26, R27, R28, R31, Z14', and Z15' are each independently (c) selected from the group consisting of hydrogen, hydroxy, cyano, 10 nitro, halo, oxo, C1-C6 alkyl, C1-C6 alkyl-COOR12, C1-C6 alkoxy, C₁-C₆ haloalkyl, C₁-C₆ haloalkyloxy, C₃-C₇ cycloalkyl, optionally substituted aryloxy, optionally substituted aryl-C₀₋₄-alkyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, C(O)R13, COOR14, OC(O)R15, OS(O)₂R16, N(R17)₂, 15 NR18C(O)R19, NR20SO₂R21, SR22, S(O)R23, S(O)₂R24, and S(O)₂N(R25)₂; R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24 and R25 are each independently selected from the group consisting of hydrogen, C1-C6 alkyl and aryl; R2 is selected from the group consisting of C_0 - C_8 alkyl and $C_{1\text{-}6\text{-}}$ (d) 20 heteroalkyl; X is selected from the group consisting of a bond, O, S, S(O)₂ and N; (e) U is an aliphatic linker wherein one carbon atom of the aliphatic **(f)** linker may be replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with R30; 25 Y is selected from the group consisting of C, O, S, NH and a single (g) bond; (h) E is C(R3)(R4)A or A and wherein (i) A is selected from the group consisting of C₀-C₆ alkylcarboxyl, C₀-C₆ alkyltetrazole, C₁-C₆ alkylnitrile, C₀-C₆ alkylcarboxamide, 30 $C_0\text{-}C_6$ alkylsulfonamide and $C_0\text{-}C_6$ alkylacylsulfonamide; wherein

C₀-C₆ alkylsulfonamide, C₀-C₆ alkylacylsulfonamide and C₀-C₆

10

15


25

- alkyltetrazole are each optionally substituted with from one to two groups independently selected from R⁷;
- (ii) each R⁷ is independently selected from the group consisting of hydrogen, C₁-C₆ haloalkyl, aryl-C₀-C₄ alkyl and C₁-C₆ alkyl, wherein such alkyl and arylalkyl are each optionally substituted with from one to two groups independently selected from R7'; each R7' is independently selected from halo, C₁-C₆ alkyl, and haloC₁-C₆ alkyl;
- (iii) R3 is selected from the group consisting of hydrogen, C₁-C₅ alkyl, and C₁-C₅ alkoxy; and
- (iv) R4 is selected from the group consisting of hydrogen, C₁-C₅ alkyl, C₁-C₅ alkoxy, aryloxy, C₃-C₆ cycloalkyl, and aryl C₀-C₄ alkyl, and R3 and R4 are optionally combined to form a C₃-C₄ cycloalkyl, and wherein alkyl, alkoxy, cycloalkyl and aryl-alkyl are each optionally substituted with one to three each independently selected from R26;
- (i) Z5 is S or O;
- Z12 is selected from the group consisting of hydrogen and -Z13C₀−
 C₃alkylZ14;
- 20 (k) Z13 is selected from the group consisting of a single bond, CO, CO₂, CONZ15, and SO₂;
 - (l) Z14 is selected from the group consisting of aryl and heteroaryl, wherein the aryl and heteroaryl is each optionally substituted with from one to three substituents independently selected from Z14';
 - (m) Z15 is selected from the group consisting of hydrogen aryl and heteroaryl, wherein the aryl and heteroaryl is each optionally substituted with from one to three substituents independently selected from Z15';
 - (n) R9 is selected from the group consisting of hydrogen, C₁-C₄ alkyl, C₁-C₄ alkylenyl, halo, aryl-C₀-C₄ alkyl, heteroaryl, C₁-C₆ allyl, and OR29, and wherein aryl-C₀-C₄ alkyl, heteroaryl are each optionally

20


substituted with from one to three independently selected from R27; R29 is selected from the group consisting of hydrogen and C_1 - C_4 alkyl;

- (o) R10, R11 are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C₁-C₆ alkyl, C₀-C₆ alkyl-COOR12", C₁-C₆ alkoxy, C₁-C₆ haloalkyl, C₁-C₆ haloalkyloxy, C₃-C₇ cycloalkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, C3-C6 cycloalkylaryl-C₀₋₂-alkyl, aryloxy, C(O)R13', COOR14', OC(O)R15', OS(O)₂R16', N(R17')₂, NR18'C(O)R19', NR20'SO₂R21', SR22', S(O)R23', S(O)₂R24', and S(O)₂N(R25')₂; and wherein aryl-C₀₋₄-alkyl, aryl- C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C3-C6 cycloalkylaryl-C₀₋₂-alkyl are each optionally substituted with from one to three independently selected from R28;
 - (p) R12', R12'', R13', R14', R15', R16', R17', R18', R19', R20', R21', R22', R23', R24', and R25' are each independently selected from the group consisting of hydrogen, C₁-C₆ alkyl and aryl;
 - (q) R30 is selected from the group consisting of C₁-C₆ alkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C3-C6 cycloalkylaryl-C₀₋₂-alkyl, and wherein C₁-C₆ alkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C3-C6 cycloalkylaryl-C₀₋₂-alkyl are each optionally substituted with from one to three substituents each independently selected from R31;
 - (r) R32 is selected from the group consisting of a bond, hydrogen, halo, C₁-C₆ alkyl, C₁-C₆ haloalkyl, and C₁-C₆ alkyloxo;
- 25 (s) R33 is selected from the group consisting of C2-C8 alkyl, C1-C8




alkoxy, phenyl, thiophene, pyridine, piperidine,

, wherein the C2-C8 alkyl, C1-C8



alkoxy, phenyl, thiophene, pyridine, piperidine,




, and , are each optionally substituted with R10

and R11.

5

- 48. The compound of Claim 47, wherein A is selected from the group consisting of C₀-C₆ alkylcarboxyl, C₀-C₆ alkyltetrazole, C₁-C₆ alkylnitrile, C₀-C₆ alkylsulfonamide and C₀-C₆ alkylacylsulfonamide; wherein C₀-C₆ alkylsulfonamide, C₀-C₆ alkylacylsulfonamide and C₀-C₆ alkyltetrazole are each optionally substituted with from one to two groups independently selected from R⁷.
- 49. The compound of Claim 47, wherein the compound is represented by the following Structural Formula:

15



10


15

20

25

and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein:

(a) T1 is selected from the group consisting of



- (b) R1 is selected from the group consisting of hydrogen, C₁-C₈ alkyl, C₁-C₈ alkenyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C₃-C₆ cycloalkylaryl-C₀₋₂-alkyl, wherein C₁-C₈ alkyl, C₁-C₈ alkenyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C₃-C₆ cycloalkylaryl-C₀₋₂-alkyl are each optionally substituted with from one to three substituents independently selected from R1':
- (c) R1', R26, R27, R28, R31, Z14', and Z15' are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C₁-C₆ alkyl, C₁-C₆ alkyl-COOR12, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, C₁-C₆ haloalkyloxy, C₃-C₇ cycloalkyl, aryloxy, aryl-C₀-4-alkyl, heteroaryl, heterocycloalkyl, C(O)R13, COOR14, OC(O)R15, OS(O)₂R16, N(R17)₂, NR18C(O)R19, NR20SO₂R21, SR22, S(O)R23, S(O)₂R24, and S(O)₂N(R25)₂; R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24 and R25 are each independently selected from the group consisting of hydrogen, C₁-C₆ alkyl and aryl;
- (d) R2 is selected from the group consisting of C_0 - C_8 alkyl and C_{1-6} -heteroalkyl;
- (e) X is selected from the group consisting of a bond, O, S, S(O)₂ and N;

	(f)	U is an aliphatic linker wherein one carbon atom of the aliphatic
		linker may be replaced with O, NH or S, and wherein such aliphatic
		linker is optionally substituted with R30;
	(g)	Y is selected from the group consisting of C, O, S, NH and a single
5		bond;
	(h)	E is C(R3)(R4)A or A and wherein
		(i) A is selected from the group consisting of carboxyl, tetrazole,
		C ₁ -C ₆ alkylnitrile, carboxamide, sulfonamide and
		acylsulfonamide; wherein sulfonamide, acylsulfonamide and
10		tetrazole are each optionally substituted with from one to two
		groups independently selected from R ⁷ ;
	•	(ii) each R ⁷ is independently selected from the group consisting of
		hydrogen, C_1 - C_6 haloalkyl, aryl- C_0 - C_4 alkyl and C_1 - C_6 alkyl,
		wherein such alkyl and arylalkyl are each optionally substituted
15		with from one to two groups independently selected from R7';
		each R7' is independently selected from halo, C1-C6 alkyl, and
		$haloC_1-C_6$ alkyl;
		(iii) R3 is selected from the group consisting of hydrogen, C1-C5
		alkyl, and C ₁ -C ₅ alkoxy; and
20		(iv) R4 is selected from the group consisting of hydrogen, C ₁ -C ₅
		alkyl, C_1 - C_5 alkoxy, aryloxy, C_3 - C_6 cycloalkyl, and aryl C_0 - C_4
		alkyl, and R3 and R4 are optionally combined to form a C3-C4
		cycloalkyl, and wherein alkyl, alkoxy, cycloalkyl and aryl-alkyl
		are each optionally substituted with one to three each
25	1	independently selected from R26;
	(i)	Z5 is S or O;
	(j)	Z12 is selected from the group consisting of hydrogen and -Z13C ₀ -
		C₃alkylZ14;
	(k)	Z13 is selected from the group consisting of a single bond, CO, CO ₂ ,
30		CONZ15, and SO ₂ ;

10

15


20

25


- (1) Z14 is selected from the group consisting of aryl and heteroaryl, wherein the aryl and heteroaryl is each optionally substituted with from one to three substituents independently selected from Z14';
- (m) Z15 is selected from the group consisting of hydrogen aryl and heteroaryl, wherein the aryl and heteroaryl is each optionally substituted with from one to three substituents independently selected from Z15';
- (n) R9 is selected from the group consisting of hydrogen, C₁-C₄ alkyl, C₁-C₄ alkylenyl, halo, aryl-C₀-C₄ alkyl, heteroaryl, C₁-C₆ allyl, and OR29, and wherein aryl-C₀-C₄ alkyl, heteroaryl are each optionally substituted with from one to three independently selected from R27; R29 is selected from the group consisting of hydrogen and C₁-C₄ alkyl;
- (o) R10, R11 are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C₁-C₆ alkyl, C₀-C₆ alkyl-COOR12", C₁-C₆ alkoxy, C₁-C₆ haloalkyl, C₁-C₆ haloalkyloxy, C₃-C₇ cycloalkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, C₃-C₆ cycloalkylaryl-C₀₋₂-alkyl, aryloxy, C(O)R13', COOR14', OC(O)R15', OS(O)₂R16', N(R17')₂, NR18'C(O)R19', NR20'SO₂R21', SR22', S(O)R23', S(O)₂R24', and S(O)₂N(R25')₂; and wherein aryl-C₀₋₄-alkyl, aryl- C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C₃-C₆ cycloalkylaryl-C₀₋₂-alkyl are each optionally substituted with from one to three independently selected from R28;
 - (p) R12', R12", R13', R14', R15', R16', R17', R18', R19', R20', R21', R22', R23', R24', and R25' are each independently selected from the group consisting of hydrogen, C₁-C₆ alkyl and aryl;
- (q) R30 is selected from the group consisting of C₁-C₆ alkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C3-C6 cycloalkylaryl-C₀₋₂-alkyl, and wherein C₁-C₆ alkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C3-C6

cycloalkylaryl-C₀₋₂-alkyl are each optionally substituted with from one to three substituents each independently selected from R31;


- (r) R32 is selected from the group consisting of a bond, hydrogen, halo, C₁-C₆ alkyl, C₁-C₆ haloalkyl, and C₁-C₆ alkyloxo;
- (s) R33 is selected from the group consisting of phenyl, thiophene,



pyridine, piperidine,




wherein the phenyl, thiophene, pyridine, piperidine,



and R11.

10

50. The compound of Claim 47, wherein the compound is represented by the following Structural Formula:



15 51. The compound of Claim 50, wherein the compound is represented by the following Structural Formula:

WO 2004/092131

5

10

15

52. The compound of Claim 51, wherein the compound is represented by the following Structural Formula:

53. The compound of Claim 52, wherein X is a bond.

54. The compound of Claim 52, wherein X is -S-.

55. The compound of Claim 52, wherein X is -O-.

56. The compound of Claim 55 wherein E is -COOH, C₁-C₆ alkylcarboxyl, or C(R3)(R4)-C₁-C₆ alkyl-COOH.

57. The compound of Claim 56 wherein R10 and R11 are each independently selected from the group consisting of hydrogen, halo, oxo, C₁-C₆ alkyl, C₁-C₆ alkyl-COOR12", C₁-C₆ alkoxy, C₁-C₆ haloalkyl, and C₁-C₆ haloalkyloxy.

The compound of Claim 57 wherein R10 is selected from the group consisting of C₃-C₇ cycloalkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, C₃-C₆ cycloalkylaryl-C₀₋₂-alkyl, and aryloxy.

10

- 59. The compound of Claim 58, wherein R10 is CF₃.
- 60. The compound of Claim 57, wherein R9 is selected from the group consisting of hydrogen and C₁-C₃ alkyl.
- 61. The compound of Claim 60, wherein R1, R3, and R4 are each independently selected from the group consisting of hydrogen and C₁-C₂ alkyl.
- 62. The compound of Claim 61 wherein R2 is a bond.
- 63. The compound of Claim 62, wherein U is: saturated C₁-C₃ alkyl; and optionally substituted with C₁-C₃ alkyl.
- 15 64. The compound of Claim 51, wherein the compound is represented by the following Structural Formula:

$$\begin{array}{c|c}
 & R1 \\
 & R9 \\
\hline
 & R10 \\
\hline
 & R10 \\
\hline
 & R10 \\
\hline
 & R11 \\
\hline
 & R10 \\
\hline
 & R11 \\
\hline
 & R10 \\
\hline
 & R11 \\
\hline
 & R10 \\
\hline
 & R10 \\
\hline
 & R11 \\
\hline
 & R10 \\
\hline
 & R11 \\
\hline
 & R10 \\
\hline
 & R11 \\
\hline
 & R10 \\
\hline
 & R1$$

- 65. The compound of Claim 64, wherein X is a bond.
- 66. The compound of Claim 64, wherein \dot{X} is -S-.
- 67. The compound of Claim 64, wherein X is -O-.
- 25 68. The compound of Claim 67 wherein E is -COOH, C₁-C₆ alkylcarboxyl, or C(R3)(R4)-C₁-C₆ alkyl-COOH.

- 69. The compound of Claim 68 wherein R10 and R11 are each independently selected from the group consisting of hydrogen, halo, oxo, C₁-C₆ alkyl, C₁-C₆ alkyl-COOR12", C₁-C₆ alkoxy, C₁-C₆ haloalkyl, and C₁-C₆ haloalkyloxy.
- The compound of Claim 69 wherein R10 is selected from the group consisting of C₃-C₇ cycloalkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, C₃-C₆ cycloalkylaryl-C₀₋₂-alkyl, and aryloxy.
 - 71. The compound of Claim 70, wherein R10 is CF₃.

10

- 72. The compound of Claim 69, wherein R9 is selected from the group consisting of hydrogen and C_1 - C_3 alkyl.
- 73. The compound of Claim 72, wherein R1, R3, and R4 are each independently selected from the group consisting of hydrogen and C₁-C₂ alkyl.
 - 74. The compound of Claim 73 wherein R2 is a bond.
- 75. The compound of Claim 74, wherein U is:
 20 saturated C₁-C₃ alkyl; and optionally substituted with C₁-C₃ alkyl.
 - 76. The compound of Claim 51, wherein the compound is represented by the following Structural Formula:

77. The compound of Claim 76, wherein X is a bond.

- 78. The compound of Claim 76, wherein X is -S-.
- 79. The compound of Claim 76, wherein X is -O-.

15

- 80. The compound of Claim 33 wherein E is -COOH, C₁-C₆ alkylcarboxyl, or C(R3)(R4)-C₁-C₆ alkyl-COOH.
- 81. The compound of Claim 80 wherein R10 and R11 are each independently selected from the group consisting of hydrogen, halo, oxo, C₁-C₆ alkyl, C₁-C₆ alkyl-COOR12", C₁-C₆ alkoxy, C₁-C₆ haloalkyl, and C₁-C₆ haloalkyloxy.
 - 82. The compound of Claim 81 wherein R10 is selected from the group consisting of C₃-C₇ cycloalkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, C3-C6 cycloalkylaryl-C₀₋₂-alkyl, and aryloxy.
 - 83. The compound of Claim 82, wherein R10 is CF₃.
- 84. The compound of Claim 81, wherein R9 is selected from the group consisting of hydrogen and C₁-C₃ alkyl.
 - 85. The compound of Claim 84, wherein R1, R3, and R4 are each independently selected from the group consisting of hydrogen and C₁-C₂ alkyl.
- 25 86. The compound of Claim 85 wherein R2 is a bond.
 - 87. The compound of Claim 86, wherein U is: saturated C₁-C₃ alkyl; and optionally substituted with C₁-C₃ alkyl.

30

88. The compound of Claim 47 wherein the compound is selected from the group consisting of:

{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1yl}-acetic acid; [5-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-indol-1-yl]-acetic acid; {5-[2-(4-Fluoro-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-acetic 5 acid; {5-[2-(4-Benzyloxy-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}acetic acid; 2-Methyl-2-(5-{2-[2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]ethoxy}-indol-1-yl)-propionic acid: $\label{thyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-\\$ 10 acetic acid; $\hbox{2-Methyl-2-(5-\{2-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-(4-trifluoromet$ ylmethoxy]-ethoxy}-indol-1-yl)-propionic acid; {5-[2-(3,5-Bis-trifluoromethyl-phenyl)-4-methyl-thiazol-5-ylmethoxy]-15 indol-1-yl}-acetic acid: {5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-indol-1yl}-acetic acid: 2-Methyl-2-{5-[4-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-5ylmethoxy]-indol-1-yl}-propionic acid; Racemic 2-{5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-20 indol-1-yl}-propionic acid; {5-[2-(4-Bromo-phenyl)-4-methyl-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid: $\label{thm:control} \ensuremath{\{5\text{-}[4\text{-}Butyl\text{-}2\text{-}(4\text{-}trifluoromethyl\text{-}phenyl)\text{-}thiazol\text{-}5\text{-}ylmethoxy}]\text{-}indol\text{-}1\text{-}yl}\ensuremath{\}\text{-}indol\text{-}2\text{-}yl}\ensuremath{}\text{-}2\text{-}yl}\ensuremath{$ -} 25 acetic acid; 2-{5-[4-Butyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1yl}-propionic acid; {5-[4-Phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1yl}-acetic acid; 2-{5-[4-(2-Chloro-6-fluoro-phenoxymethyl)-2-(4-trifluoromethyl-phenyl)-30

thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;

{5-[4-Phenoxymethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]indol-1-yl}-acetic acid: Racemic 2-Methyl-2-{5-[4-phenoxymethyl-2-(4-trifluoromethyl-phenyl)thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid; 5 2-Methyl-2-{5-[4-phenoxymethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5ylmethoxy]-indol-1-yl}-propionic acid; 3-{5-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1yl}-propionic acid; 5-{5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-10 yl}-pentanoic acid: 5-{5-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1yl}-pentanoic acid; {5-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1yl}-acetic acid: 15 {5-[4-(2-Chloro-6-fluoro-phenoxymethyl)-2-(4-trifluoromethyl-phenyl)thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid; 2-{5-[4-(2-Chloro-6-fluoro-phenoxymethyl)-2-(4-trifluoromethyl-phenyl)thiazol-5-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid; 5-{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1-20 yl}-pentanoic acid; pentanoic acid: 5-{5-[4-Phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-pentanoic acid; 4-[1-(4-Carboxy-butyl)-1H-indol-5-yloxymethyl]-2-(4-trifluoromethyl-25 phenyl)-thiazole-5-carboxylic acid; $3-\{5-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl\}-1-yl-oxazol-4-ylmethoxyl-indol-1-yl-oxazol-4-yl-oxaz$ propionic acid; 3-{5-[4-Phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-30 1-yl}-propionic acid; 3-{5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-

yl}-propionic acid:

4-[1-(2-Carboxy-ethyl)-1H-indol-5-yloxymethyl]-2-(4-trifluoromethylphenyl)-thiazole-5-carboxylic acid; {5-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]indol-1-yl}-acetic acid; $\label{eq:continuous} \ensuremath{\{5\mbox{-}[4\mbox{-}Ethyl\mbox{-}2\mbox{-}(4\mbox{-}trifluoromethyl\mbox{-}phenyl\mbox{)}\mbox{-}oxazol\mbox{-}5\mbox{-}ylmethoxy]\mbox{-}indol\mbox{-}1\mbox{-}yl\}\mbox{-}}$ 5 acetic acid: (5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1yl)-acetic acid; {5-[2-(5-Methyl-2-pyridin-4-yl-thiazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid; {5-[2-(5-Methyl-2-morpholin-4-yl-thiazol-4-yl)-ethoxy]-indol-1-yl}-acetic 10 acid; $(5-\{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy\}-indol-1-gradient (5-\{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy\}-indol-1-gradient (5-\{2-[5-Methyl-2-(4-trifluoromethyl-phenyl-phe$ yl)-acetic acid; (5-{2-[5-Methyl-2-(tetrahydro-pyran-4-yl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-15 acetic acid: {5-[2-(2-Butoxy-5-methyl-oxazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid; {5-[2-(5-Methyl-2-pyridin-3-yl-thiazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid; {5-[2-(5-Methyl-2-pyridin-2-yl-thiazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid; $(5-\{2-[2-(5-Bromo-thiophen-2-yl)-5-methyl-oxazol-4-yl]-ethoxy\}-indol-1-yl-oxazol-4-yl-ox$ 20 yl)-acetic acid; {5-[3-(4-Butyl-phenoxy)-propoxy]-indol-1-yl}-acetic acid; (5-{2-[2-(3-Bromo-phenyl)-5-methyl-oxazol-4-yl]-ethoxy}-indol-1-yl)acetic acid: (5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1-25 yl)-acetic acid: $2-(5-\{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy\}-indol-1$ yl)-propionic acid: (5-{2-[2-(2-Chloro-phenyl)-5-ethyl-thiazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid; 2-(5-{2-[2-(2-Chloro-phenyl)-5-ethyl-thiazol-4-yl]-ethoxy}-indol-1-yl)-30

propionic acid;

(5-{2-[5-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1yl)-acetic acid; 2-(5-{2-[5-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid: 5 $2-(5-\{2-[2-(2-Chloro-phenyl)-5-ethyl-thiazol-4-yl]-ethoxy\}-indol-1-yl)-2-indol-1-yl-2-indol-1$ methyl-propionic acid: Racemic 2-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]ethoxy}-indol-1-yl)-propionic acid; (5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-10 yl)-acetic acid: 2-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1yl)-2-methyl-propionic acid: 3-(5-{2-[2-(2-Chloro-phenyl)-5-ethyl-thiazol-4-yl]-ethoxy}-indol-1-yl)propionic acid: $3-(5-\{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy\}-indol-1-i$ 15 yl)-propionic acid: $2-Methyl-2-(5-\{2-[5-propyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-1-(4-trifluoromethyl-phenyl)-thiazol-4$ ethoxy}-indol-1-yl)-propionic acid; Racemic-(5-{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-20 ethoxy}-indol-1-yl)-acetic acid; Racemic-(5-{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]ethoxy}-indol-1-yl)-acetic acid; Racemic-(5-{1-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]ethoxy}-indol-1-yl)-acetic acid; Racemic-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-1-25 methyl-ethoxy}-indol-1-yl)-acetic acid; Racemic-(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]propoxy}-indol-1-yl)-acetic acid; (5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-propoxy}-indol-30 1-yl)-acetic acid; (S)- $(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-propoxy}-$

indol-1-yl)-acetic acid;

(R)-(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-propoxy}indol-1-yl)-acetic acid; Racemic-(5-{1-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]ethoxy}-indol-1-yl)-acetic acid: Racemic-(5-{1-[4-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-yl]-ethoxy}-5 indol-1-yl)-acetic acid: $\label{eq:continuous} \ensuremath{\texttt{5-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-\\$ acetic acid: Racemic-2-{5-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-10 indol-1-yl}-propionic acid; 2-Methyl-2-{5-[4-propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]indol-1-yl}-propionic acid: Racemic-2-{5-[4-Phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5ylmethoxy]-indol-1-yl}-propionic acid; 2-Methyl-2-{5-[4-phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-15 ylmethoxy]-indol-1-yl}-propionic acid; ${\it \{5-[4-Phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-thiazol-5-ylmethoxy]-indol-1-thiazol-5-ylmethoxyl-5-ylmethoxyl-indol-1-thiazol-5-ylmethoxyl-5-ylmethoxyl-5-ylme$ yl}-acetic acid; {5-[4-Phenyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-20 yl}-acetic acid; {5-[4-tert-Butyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1yl}-acetic acid: {5-[4-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-2-(4-trifluoromethyl-phenyl)thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid; 25 2-Methyl-2-[5-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-indol-1-yl]propionic acid: 2-{5-[2-(4-Trifluoromethyl-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1yl}-2-methyl-propionic acid: $2-\{5-[2-(4-Fluoro-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl\}-2-indol-1-yl\}-2-indol-1-yl\}-2-indol-1-yl\}-2-indol-1-yl\}-2-indol-1-yl\}-2-indol-1-yl\}-2-indol-1-yl\}-2-indol-1-yl\}-2-indol-1-yl\}-2-indol-1-yl\}-2-indol-1-yl\}-2-indol-1-yl\}-2-indol-1-yl\}-2-indol-1-yl]-2-i$ 30 methyl-propionic acid;

2-{5-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-2-

methyl-propionic acid;

2-Methyl-2-(5-{2-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]ethoxy}-indol-1-yl)-propionic acid; $2-(5-\{2-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-yl]-ethoxy\}-indol-1-yl)-2-indol-1-yl)$ methyl-propionic acid: 5 $2\hbox{-}(5\hbox{-}\{2\hbox{-}[2\hbox{-}(5\hbox{-Bromo-thiophen-}2\hbox{-}yl)\hbox{-}5\hbox{-methyl-}oxazol\hbox{-}4\hbox{-}yl]\hbox{-}ethoxy}\}\hbox{-}indol\hbox{-}l$ yl)-2-methyl-propionic acid; 2-Methyl-2-{5-[2-(5-methyl-2-phenyl-thiazol-4-yl)-ethoxy]-indol-1-yl}propionic acid: {5-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-2-10 methyl-indol-1-yl}-acetic acid: 2-{5-[2-(3,5-Bis-trifluoromethyl-phenyl)-4-methyl-thiazol-5-ylmethoxy]indol-1-yl}-2-methyl-propionic acid; $\{4\hbox{-}[4\hbox{-}Propyl\hbox{-}2\hbox{-}(4\hbox{-}trifluoromethyl\hbox{-}phenyl)\hbox{-}thiazol\hbox{-}5\hbox{-}ylmethoxy}]\hbox{-}indol\hbox{-}1\hbox{-}yl\}\hbox{-}indol\hbox{-}1\hbox{-}yl\}\hbox{-}indol\hbox{-}2\hbox{-}ylmethoxy}.$ acetic acid: Racemic-(5-{1-[4-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-2-(4-15 trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid; Racemic-(5-{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-2phenyl-ethoxy}-indol-1-yl)-acetic acid; Racemic-(5-{1-[4-Phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-20 ethoxy}-indol-1-yl)-acetic acid: 2-{5-[4-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1yl}-2-methyl-propionic acid; (R)-(5-{1-[4-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-2-(4-trifluoromethylphenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid; $(S)-(5-\{1-[4-[2-(2-Chloro-6-fluoro-phenyl]-2-(4-trifluoromethyl-2-(4-t$ 25 phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid; ethoxy}-indol-1-yl)-acetic acid; (R)- $(5-\{1-[4-[2-phenylethyl]-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-$ 30 ethoxy}-indol-1-yl)-acetic acid; (S)-(5-{1-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-

indol-1-yl)-acetic acid;

WO 2004/092131

10

25

30

PCT/US2003/041698

(R)-(5-{1-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

- 228 -


- (R)-(5-{1-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;
- 5 (R)-(5-{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;
 - (S)-(5-{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;
 - (S)-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-1-methylethoxy}-indol-1-yl)-acetic acid;
 - (R)-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl}-1-methylethoxy}-indol-1-yl)-acetic acid;
 - N-(2-{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-l-yl}-acetyl)-methanesulfonamide;
- N-(2-{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indoll-yl}-acetyl)-benzenesulfonamide; and
 - N-[2-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1-yl)-acetyl]-methanesulfonamide.
- 20 89. The compound of Claim 47, wherein the compound is in the S conformation.
 - 90. The compound of Claim 47, wherein the compound is in the R conformation.
 - 91. The compound of Claim 47, wherein the compound is radiolabeled.
 - 92. A method of treating a mammal in need of treatment for a disease, wherein the disease is treatable by modulating a peroxisome proliferator activated receptor, comprising the step of administering to the mammal in need thereof a therapeutically effective amount of a compound represented by the following Structural Formula:

WO 2004/092131

and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein:

5

(a) T1 is selected from the group consisting of



10

(b) R1 is selected from the group consisting of hydrogen, C₁-C₈ alkyl, C₁-C₈ alkenyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C₃-C₆ cycloalkylaryl-C₀₋₂-alkyl, wherein C₁-C₈ alkyl, C₁-C₈ alkenyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C₃-C₆ cycloalkylaryl-C₀₋₂-alkyl are each optionally substituted with from one to three substituents independently selected from R1':

15

(c) R1', R26, R27, R28, R31, Z14', and Z15' are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C₁-C₆ alkyl, C₁-C₆ alkyl-COOR12, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, C₁-C₆ haloalkyloxy, C₃-C₇ cycloalkyl, optionally substituted aryloxy, optionally substituted aryl-C₀₋₄-alkyl, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, C(O)R13, COOR14, OC(O)R15, OS(O)₂R16, N(R17)₂, NR18C(O)R19, NR20SO₂R21, SR22, S(O)R23, S(O)₂R24, and S(O)₂N(R25)₂; R12, R13, R14, R15, R16, R17, R18, R19, R20, R21,

R22, R23, R24 and R25 are each independently selected from the group consisting of hydrogen, C₁-C₆ alkyl and aryl; R2 is selected from the group consisting of C_0 - C_8 alkyl and C_{1-6} -(d) heteroalkyl: 5 X is selected from the group consisting of a bond, O, S, S(O)₂ and N; (e) U is an aliphatic linker wherein one carbon atom of the aliphatic **(f)** linker may be replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with R30; Y is selected from the group consisting of C, O, S, NH and a single (g) 10 bond; (h) E is C(R3)(R4)A or A and wherein (i) A is selected from the group consisting of C₀-C₆ alkylcarboxyl, C₀-C₆ alkyltetrazole, C₁-C₆ alkylnitrile, C₀-C₆ alkylcarboxamide, $C_0\text{-}C_6$ alkylsulfonamide and $C_0\text{-}C_6$ alkylacylsulfonamide; wherein 15 C₀-C₆ alkylsulfonamide, C₀-C₆ alkylacylsulfonamide and C₀-C₆ alkyltetrazole are each optionally substituted with from one to two groups independently selected from R⁷: (ii) each R⁷ is independently selected from the group consisting of hydrogen, C₁-C₆ haloalkyl, aryl-C₀-C₄ alkyl and C₁-C₆ alkyl, 20 wherein such alkyl and arylalkyl are each optionally substituted with from one to two groups independently selected from R7'; each R7' is independently selected from halo, C1-C6 alkyl, and haloC₁-C₆ alkyl; (iii) R3 is selected from the group consisting of hydrogen, C₁-C₅ 25 alkyl, and C1-C5 alkoxy; and (iv) R4 is selected from the group consisting of hydrogen, C_1 - C_5 alkyl, C_1 - C_5 alkoxy, aryloxy, C_3 - C_6 cycloalkyl, and aryl C_0 - C_4 alkyl, and R3 and R4 are optionally combined to form a C3-C4 cycloalkyl, and wherein alkyl, alkoxy, cycloalkyl and aryl-alkyl 30

are each optionally substituted with one to three each

independently selected from R26;

10


15

20

25


- (i) Z5 is S or O;
- Z12 is selected from the group consisting of hydrogen and -Z13C₀ C₃alkylZ14;
- Z13 is selected from the group consisting of a single bond, CO, CO₂,
 CONZ15, and SO₂;
- (1) Z14 is selected from the group consisting of aryl and heteroaryl, wherein the aryl and heteroaryl is each optionally substituted with from one to three substituents independently selected from Z14';
- (m) Z15 is selected from the group consisting of hydrogen aryl and heteroaryl, wherein the aryl and heteroaryl is each optionally substituted with from one to three substituents independently selected from Z15';
- (n) R9 is selected from the group consisting of hydrogen, C₁-C₄ alkyl, C₁-C₄ alkylenyl, halo, aryl-C₀-C₄ alkyl, heteroaryl, C₁-C₆ allyl, and OR29, and wherein aryl-C₀-C₄ alkyl, heteroaryl are each optionally substituted with from one to three independently selected from R27; R29 is selected from the group consisting of hydrogen and C₁-C₄ alkyl;
- (o) R10, R11 are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C₁-C₆ alkyl, C₀-C₆ alkyl-COOR12", C₁-C₆ alkoxy, C₁-C₆ haloalkyl, C₁-C₆ haloalkyloxy, C₃-C₇ cycloalkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, C3-C6 cycloalkylaryl-C₀₋₂-alkyl, aryloxy, C(O)R13", COOR14", OC(O)R15", OS(O)₂R16", N(R17")₂, NR18"C(O)R19", NR20"SO₂R21", SR22", S(O)R23", S(O)₂R24", and S(O)₂N(R25")₂; and wherein aryl-C₀₋₄-alkyl, aryl- C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C3-C6 cycloalkylaryl-C₀₋₂-alkyl are each optionally substituted with from one to three independently selected from R28;
- (p) R12', R12'', R13', R14', R15', R16', R17', R18', R19', R20', R21', R22', R23', R24', and R25' are each independently selected from the group consisting of hydrogen, C₁-C₆ alkyl and aryl;

- (q) R30 is selected from the group consisting of C₁-C₆ alkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C3-C6 cycloalkylaryl-C₀₋₂-alkyl, and wherein C₁-C₆ alkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C3-C6 cycloalkylaryl-C₀₋₂-alkyl are each optionally substituted with from one to three substituents each independently selected from R31;
- (r) R32 is selected from the group consisting of a bond, hydrogen, halo, C₁-C₆ alkyl, C₁-C₆ haloalkyl, and C₁-C₆ alkyloxo;
- (s) R33 is selected from the group consisting of C1-C8 alkyl, C1-C8




5


alkoxy, phenyl, thiophene, pyridine, piperidine,



, wherein the C1-C8 alkyl, C1-C8



alkoxy, phenyl, thiophene, pyridine, piperidine,



, are each optionally substituted with R10

and R11.

15

93. The method of Claim 93, wherein the compound is represented by the following Structural Formula:

10

15

and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein:

(a) T1 is selected from the group consisting of

- (b) R1 is selected from the group consisting of hydrogen, C₁-C₈ alkyl, C₁-C₈ alkenyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C₃-C₆ cycloalkylaryl-C₀₋₂-alkyl, wherein C₁-C₈ alkyl, C₁-C₈ alkenyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C₃-C₆ cycloalkylaryl-C₀₋₂-alkyl are each optionally substituted with from one to three substituents independently selected from R1';
- (c) R1', R26, R27, R28, R31, Z14', and Z15' are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C₁-C₆ alkyl, C₁-C₆ alkyl-COOR12, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, C₁-C₆ haloalkyloxy, C₃-C₇ cycloalkyl, aryloxy, aryl-C₀-4-alkyl, heteroaryl, heterocycloalkyl, C(O)R13, COOR14, OC(O)R15, OS(O)₂R16, N(R17)₂, NR18C(O)R19, NR20SO₂R21, SR22, S(O)R23, S(O)₂R24, and S(O)₂N(R25)₂; R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24 and R25 are each

- independently selected from the group consisting of hydrogen, C1-C6 alkyl and aryl; R2 is selected from the group consisting of C_0 - C_8 alkyl and $C_{1\text{-}6\text{-}}$ (d) heteroalkyl; 5 X is selected from the group consisting of a bond, O, S, S(O)₂ and N; (e) U is an aliphatic linker wherein one carbon atom of the aliphatic (f) linker may be replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with R30; Y is selected from the group consisting of C, O, S, NH and a single (g) 10 bond; (h) E is C(R3)(R4)A or A and wherein (i) A is selected from the group consisting of carboxyl, tetrazole, C₁-C₆ alkylnitrile, carboxamide, sulfonamide and acylsulfonamide; wherein sulfonamide, acylsulfonamide and 15 tetrazole are each optionally substituted with from one to two groups independently selected from R⁷; (ii) each R⁷ is independently selected from the group consisting of hydrogen, C_1 - C_6 haloalkyl, aryl- C_0 - C_4 alkyl and C_1 - C_6 alkyl, wherein such alkyl and arylalkyl are each optionally substituted 20 with from one to two groups independently selected from R7'; each R7' is independently selected from halo, C1-C6 alkyl, and haloC₁-C₆ alkyl; (iii) R3 is selected from the group consisting of hydrogen, C₁-C₅ alkyl, and C1-C5 alkoxy; and 25 (iv) R4 is selected from the group consisting of hydrogen, C₁-C₅ alkyl, C_1 - C_5 alkoxy, aryloxy, C_3 - C_6 cycloalkyl, and aryl C_0 - C_4 alkyl, and R3 and R4 are optionally combined to form a C3-C4 cycloalkyl, and wherein alkyl, alkoxy, cycloalkyl and aryl-alkyl are each optionally substituted with one to three each 30 independently selected from R26;
 - (i) Z5 is S or O;

10

15

20


25

- Z12 is selected from the group consisting of hydrogen and -Z13C₀-C₃alkylZ14;
- Z13 is selected from the group consisting of a single bond, CO, CO₂,
 CONZ15, and SO₂;
- (l) Z14 is selected from the group consisting of aryl and heteroaryl, wherein the aryl and heteroaryl is each optionally substituted with from one to three substituents independently selected from Z14';
 - (m) Z15 is selected from the group consisting of hydrogen aryl and heteroaryl, wherein the aryl and heteroaryl is each optionally substituted with from one to three substituents independently selected from Z15';
 - (n) R9 is selected from the group consisting of hydrogen, C₁-C₄ alkyl, C₁-C₄ alkylenyl, halo, aryl-C₀-C₄ alkyl, heteroaryl, C₁-C₆ allyl, and OR29, and wherein aryl-C₀-C₄ alkyl, heteroaryl are each optionally substituted with from one to three independently selected from R27; R29 is selected from the group consisting of hydrogen and C₁-C₄ alkyl;
 - (o) R10, R11 are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C₁-C₆ alkyl, C₀-C₆ alkyl-COOR12", C₁-C₆ alkoxy, C₁-C₆ haloalkyl, C₁-C₆ haloalkyloxy, C₃-C₇ cycloalkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, C3-C6 cycloalkylaryl-C₀₋₂-alkyl, aryloxy, C(O)R13", COOR14", OC(O)R15", OS(O)₂R16", N(R17")₂, NR18"C(O)R19", NR20"SO₂R21", SR22", S(O)R23", S(O)₂R24", and S(O)₂N(R25")₂; and wherein aryl-C₀₋₄-alkyl, aryl- C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C3-C6 cycloalkylaryl-C₀₋₂-alkyl are each optionally substituted with from one to three independently selected from R28;
 - (p) R12', R12", R13', R14', R15', R16', R17', R18', R19', R20', R21',
 R22', R23', R24', and R25' are each independently selected from the group consisting of hydrogen, C₁-C₆ alkyl and aryl;

WO 2004/092131 PCT/US2003/041698

- 236 -

- (q) R30 is selected from the group consisting of C₁-C₆ alkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C3-C6 cycloalkylaryl-C₀₋₂-alkyl, and wherein C₁-C₆ alkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, and C3-C6 cycloalkylaryl-C₀₋₂-alkyl are each optionally substituted with from one to three substituents each independently selected from R31;
- (r) R32 is selected from the group consisting of a bond, hydrogen, halo, C₁-C₆ alkyl, C₁-C₆ haloalkyl, and C₁-C₆ alkyloxo;
- (s) R33 is selected from the group consisting of phenyl, thiophene,




10 pyridine, piperidine,

5



wherein the phenyl, thiophene, pyridine, piperidine,



, are each optionally substituted with R10


and R11.

- 15 94. The method of Claim 92, wherein the disease is selected from the group consisting of diabetes mellitus, Syndrome X, and atherosclerosis.
 - 95. The method of Claim 94, wherein the disease is diabetes mellitus.
- 20 96. The method of Claim 94, wherein the disease is Syndrome X.

WO 2004/092131 PCT/US2003/041698

- 237 -

97. The method of Claim 93, wherein the compound is represented by the following Structural Formula:



5 98. The method of Claim 94, wherein the compound is represented by the following Structural Formula:

99. The method of Claim 98, wherein the compound is represented by the following Structural Formula:

10

15

100. The method of Claim 99, wherein the compound is represented by the following Structural Formula:

- 101. The method of Claim 100, wherein X is a bond.
- 102. The method of Claim 100, wherein X is -S-.

- 103. The method of Claim 100, wherein X is -O-.
- 104. The method of Claim 103 wherein E is -COOH, C₁-C₆ alkylcarboxyl, or C(R3)(R4)-C₁-C₆ alkyl-COOH.

10

- 105. The method of Claim 104 wherein R10 and R11 are each independently selected from the group consisting of hydrogen, halo, oxo, C₁-C₆ alkyl, C₁-C₆ alkyl-COOR12", C₁-C₆ alkoxy, C₁-C₆ haloalkyl, and C₁-C₆ haloalkyloxy.
- 15 106. The method of Claim 105 wherein R10 is selected from the group consisting of C₃-C₇ cycloalkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, C3-C6 cycloalkylaryl-C₀₋₂-alkyl, and aryloxy.
 - 107. The method of Claim 106, wherein R10 is CF₃.

20

- 108. The method of Claim 105, wherein R9 is selected from the group consisting of hydrogen and C₁-C₃ alkyl.
- The method of Claim 108, wherein R1, R3, and R4 are each independently selected from the group consisting of hydrogen and C₁-C₂ alkyl.
 - 110. The method of Claim 109 wherein R2 is a bond.
 - 111. The method of Claim 110, wherein U is:

30 saturated C₁-C₃ alkyl; and

optionally substituted with C1-C3 alkyl.

112. The method of Claim 99, wherein the compound is represented by the following Structural Formula:

$$R_{10}$$

- 113. The method of Claim 112, wherein X is a bond.
- 114. The method of Claim 112, wherein X is -S-.
- 10 115. The method of Claim 112, wherein X is -O-.
 - 116. The method of Claim 115 wherein E is -COOH, C₁-C₆ alkylcarboxyl, or C(R3)(R4)-C₁-C₆ alkyl-COOH.
- 15 117. The method of Claim 116 wherein R10 and R11 are each independently selected from the group consisting of hydrogen, halo, oxo, C₁-C₆ alkyl, C₁-C₆ alkyl-COOR12", C₁-C₆ alkoxy, C₁-C₆ haloalkyl, and C₁-C₆ haloalkyloxy.
- The method of Claim 117 wherein R10 is selected from the group consisting of C₃-C₇ cycloalkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, C3-C6 cycloalkylaryl-C₀₋₂-alkyl, and aryloxy.
 - 119. The method of Claim 118, wherein R10 is CF₃.
- 25 120. The method of Claim 117, wherein R9 is selected from the group consisting of hydrogen and C₁-C₃ alkyl.

- 121. The method of Claim 120, wherein R1, R3, and R4 are each independently selected from the group consisting of hydrogen and C₁-C₂ alkyl.
- 122. The method of Claim 121 wherein R2 is a bond.

- 123. The method of Claim 122, wherein U is: saturated C_1 - C_3 alkyl; and optionally substituted with C_1 - C_3 alkyl.
- 10 124. The method of Claim 99, wherein the compound is represented by the following Structural Formula:

125. The method of Claim 125, wherein X is a bond.

15

- 126. The method of Claim 124, wherein X is -S-.
- 127. The method of Claim 124, wherein X is -O-.
- 20 128. The method of Claim 127 wherein E is -COOH, C₁-C₆ alkylcarboxyl, or C(R3)(R4)-C₁-C₆ alkyl-COOH.
 - 129. The method of Claim 128 wherein R10 and R11 are each independently selected from the group consisting of hydrogen, halo, oxo, C₁-C₆ alkyl, C₁-C₆ alkyl-COOR12", C₁-C₆ alkoxy, C₁-C₆ haloalkyl, and C₁-C₆ haloalkyloxy.

WO 2004/092131 PCT/US2003/041698

- 241 -

- 130. The method of Claim 129 wherein R10 is selected from the group consisting of C₃-C₇ cycloalkyl, aryl-C₀₋₄-alkyl, aryl-C₁₋₆-heteroalkyl, heteroaryl-C₀₋₄-alkyl, C3-C6 cycloalkylaryl-C₀₋₂-alkyl, and aryloxy.
- 5 131. The method of Claim 130, wherein R10 is CF₃.
 - 132. The method of Claim 129, wherein R9 is selected from the group consisting of hydrogen and C₁-C₃ alkyl.
- 10 133. The method of Claim 132, wherein R1, R3, and R4 are each independently selected from the group consisting of hydrogen and C₁-C₂ alkyl.
 - 134. The method of Claim 133 wherein R2 is a bond.
- 15 135. The method of Claim 134, wherein U is: saturated C_1 - C_3 alkyl; and optionally substituted with C_1 - C_3 alkyl.

- 136. The method of Claim 92 wherein the compound is selected from the group consisting of:
 - {5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1-yl}-acetic acid;
 - [5-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-indol-1-yl]-acetic acid;
 - {5-[2-(4-Fluoro-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-acetic acid;
 - {5-[2-(4-Benzyloxy-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-acetic acid;
 - 2-Methyl-2-(5-{2-[2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-ethoxy}-indol-1-yl)-propionic acid;
- 30 {5-[4-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}acetic acid;

2-Methyl-2-(5-{2-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5ylmethoxy]-ethoxy}-indol-1-yl)-propionic acid; {5-[2-(3,5-Bis-trifluoromethyl-phenyl)-4-methyl-thiazol-5-ylmethoxy]indol-1-yl}-acetic acid; 5 {5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-indol-1yl}-acetic acid; 2-Methyl-2-{5-[4-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-5ylmethoxy]-indol-1-yl}-propionic acid; Racemic 2-{5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-10 indol-1-yl}-propionic acid; {5-[2-(4-Bromo-phenyl)-4-methyl-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid; {5-[4-Butyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}acetic acid; 15 2-{5-[4-Butyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1yl}-propionic acid: {5-[4-Phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1yl}-acetic acid: 2-{5-[4-(2-Chloro-6-fluoro-phenoxymethyl)-2-(4-trifluoromethyl-phenyl)-20 thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid; {5-[4-Phenoxymethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]indol-1-yl}-acetic acid; Racemic 2-Methyl-2-{5-[4-phenoxymethyl-2-(4-trifluoromethyl-phenyl)thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid; 2-Methyl-2-{5-[4-phenoxymethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-25 ylmethoxy]-indol-1-yl}-propionic acid; 3-{5-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1yl}-propionic acid: 5-{5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-30 yl}-pentanoic acid: 5-{5-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-

yl}-pentanoic acid;

{5-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1yl}-acetic acid; {5-[4-(2-Chloro-6-fluoro-phenoxymethyl)-2-(4-trifluoromethyl-phenyl)thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid; 5 2-{5-[4-(2-Chloro-6-fluoro-phenoxymethyl)-2-(4-trifluoromethyl-phenyl)thiazol-5-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid; 5-{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1yl}-pentanoic acid; $5-\{5-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl\}-1-yl-oxazol-4-ylmethoxy-1-yl-oxazol-1-yl-oxazo$ 10 pentanoic acid; 5-{5-[4-Phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-pentanoic acid: 4-[1-(4-Carboxy-butyl)-1H-indol-5-yloxymethyl]-2-(4-trifluoromethylphenyl)-thiazole-5-carboxylic acid; 3-{5-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-15 propionic acid: 3-{5-[4-Phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid; 3-{5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-20 yl}-propionic acid: 4-[1-(2-Carboxy-ethyl)-1H-indol-5-yloxymethyl]-2-(4-trifluoromethylphenyl)-thiazole-5-carboxylic acid; {5-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]indol-1-yl}-acetic acid; {5-[4-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-indol-1-yl}-25 acetic acid: $(5-\{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy\}-indol-1-in$ yl)-acetic acid; {5-[2-(5-Methyl-2-pyridin-4-yl-thiazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid; 30 {5-[2-(5-Methyl-2-morpholin-4-yl-thiazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid;

WO 2004/092131

20

- (5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;
- (5-{2-[5-Methyl-2-(tetrahydro-pyran-4-yl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;
- 5 {5-[2-(2-Butoxy-5-methyl-oxazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid;
 - {5-[2-(5-Methyl-2-pyridin-3-yl-thiazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid;
 - {5-[2-(5-Methyl-2-pyridin-2-yl-thiazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid;
 - (5-{2-[2-(5-Bromo-thiophen-2-yl)-5-methyl-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;
- 10 {5-[3-(4-Butyl-phenoxy)-propoxy]-indol-1-yl}-acetic acid;
 - (5-{2-[2-(3-Bromo-phenyl)-5-methyl-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;
 - (5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;
- 2-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;
 - (5-{2-[2-(2-Chloro-phenyl)-5-ethyl-thiazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;
 - 2-(5-{2-[2-(2-Chloro-phenyl)-5-ethyl-thiazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;
 - (5-{2-[5-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;
 - 2-(5-{2-[5-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;
- 25 2-(5-{2-[2-(2-Chloro-phenyl)-5-ethyl-thiazol-4-yl]-ethoxy}-indol-1-yl)-2-methyl-propionic acid;
 - Racemic 2-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;
 - (5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;
 - 2-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-2-methyl-propionic acid;

 $3-(5-\{2-[2-(2-Chloro-phenyl)-5-ethyl-thiazol-4-yl]-ethoxy\}-indol-1-yl)$ propionic acid; 3-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1yl)-propionic acid; 5 2-Methyl-2-(5-{2-[5-propyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]ethoxy}-indol-1-yl)-propionic acid; Racemic-(5-{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]ethoxy}-indol-1-yl)-acetic acid; Racemic-(5-{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-10 ethoxy}-indol-1-yl)-acetic acid; Racemic-(5-{1-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]ethoxy}-indol-1-yl)-acetic acid; Racemic-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-1methyl-ethoxy}-indol-1-yl)-acetic acid; Racemic-(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-15 propoxy}-indol-1-yl)-acetic acid; (5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-propoxy}-indol-1-yl)-acetic acid; 20 indol-1-yl)-acetic acid; (R)- $(5-\{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-propoxy}$ indol-1-yl)-acetic acid; Racemic-(5-{1-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]ethoxy}-indol-1-yl)-acetic acid: 25 Racemic-(6-{1-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]ethoxy}-1H-indol-3-yl)-acetic acid; Racemic-(6-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]propoxy}-1H-indol-3-yl)-acetic acid; Racemic-(1-Methyl-6-{2-[5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-30 yl]-propoxy}-1H-indol-3-yl)-acetic acid; (S)-(6-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-propoxy}-1H-indol-3-yl)-acetic acid;

(R)- $(6-\{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-propoxy}-$ 1H-indol-3-yl)-acetic acid: Racemic-(6-Hydroxy-5-{1-[4-isopropyl-2-(4-trifluoromethyl-phenyl)thiazol-5-yl]-ethyl}-1H-indol-3-yl)-acetic acid; (6-{2-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-propoxy}-1-5 methyl-1H-indol-3-yl)-acetic acid; (1-Methyl-6-{2-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]propoxy}-1H-indol-3-yl)-acetic acid; $(6-\{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-propoxy\}-1-yl-propoxy\}-1-yl-propoxy\}-1-yl-yl-propoxy\}-1-yl-propoxy\}-1-yl-propoxy\}-1-yl-propoxy\}-1-yl-propoxy\}-1-yl-propoxy\}-1-yl-propoxy\}-1-yl-propoxy\}-1-yl-propoxy\}-1-yl-propoxy\}-1-yl-propoxy\}-1-yl-propoxy\}-1-yl-propoxy\}-1-yl-propoxy]-$ 10 methyl-1H-indol-3-yl)-acetic acid; (R)- $(6-\{2-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-propoxy\}$ -1-methyl-1H-indol-3-yl)-acetic acid; (S)-(6-{2-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-propoxy}-1-methyl-1H-indol-3-yl)-acetic acid; Racemic-(1-Methyl-6-{2-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-15 yl]-propoxy}-1H-indol-3-yl)-acetic acid; $Race mic-(1-Ethyl-6-\{2-[4-isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-(4-trifl$ yl]-propoxy}-1H-indol-3-yl)-acetic acid; Racemic-(6-{2-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-20 propoxy}-1-propyl-1H-indol-3-yl)-acetic acid; Racemic-(5-{1-[4-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-yl]-ethoxy}indol-1-yl)-acetic acid: ${5-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-{1$ acetic acid: 25 Racemic-2-{5-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]indol-1-yl}-propionic acid; 2-Methyl-2-{5-[4-propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]indol-1-yl}-propionic acid: Racemic-2-{5-[4-Phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-30 ylmethoxy]-indol-1-yl}-propionic acid; 2-Methyl-2-{5-[4-phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5ylmethoxy]-indol-1-yl}-propionic acid;

{5-[4-Phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1yl}-acetic acid: {5-[4-Phenyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1yl}-acetic acid: 5 {5-[4-tert-Butyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1yl}-acetic acid: {5-[4-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-2-(4-trifluoromethyl-phenyl)thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid; 2-Methyl-2-[5-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-indol-1-yl]-10 propionic acid; 2-{5-[2-(4-Trifluoromethyl-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1yl}-2-methyl-propionic acid; 2-{5-[2-(4-Fluoro-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-2methyl-propionic acid: $\hbox{$2-\{5-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-ylmethoxy]$-indol-1-yl}-2-legal (a) the state of the state of$ 15 methyl-propionic acid; 2-Methyl-2-(5-{2-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]ethoxy}-indol-1-yl)-propionic acid; $2-(5-\{2-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-yl]-ethoxy\}-indol-1-yl)-2-indol-1-yl)-$ 20 methyl-propionic acid: $2-(5-\{2-[2-(5-Bromo-thiophen-2-yl)-5-methyl-oxazol-4-yl]-ethoxy\}-indol-1-yl-oxazol-4-yl$ yl)-2-methyl-propionic acid: 2-Methyl-2-{5-[2-(5-methyl-2-phenyl-thiazol-4-yl)-ethoxy]-indol-1-yl}propionic acid; {5-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-2-25 methyl-indol-1-yl}-acetic acid: 2-{5-[2-(3,5-Bis-trifluoromethyl-phenyl)-4-methyl-thiazol-5-ylmethoxy]indol-1-yl}-2-methyl-propionic acid; $\{4\hbox{-}[4\hbox{-}Propyl\hbox{-}2\hbox{-}(4\hbox{-}trifluoromethyl\hbox{-}phenyl)\hbox{-}thiazol\hbox{-}5\hbox{-}ylmethoxy]\hbox{-}indol\hbox{-}1\hbox{-}yl\}-indol\hbox{-}1\hbox{-}yl$ 30 acetic acid: Racemic-(5-{1-[4-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-2-(4trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;

Racemic-(5-{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-2phenyl-ethoxy}-indol-1-yl)-acetic acid; Racemic-(5-{1-[4-Phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]ethoxy}-indol-1-yl)-acetic acid; 2-{5-[4-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-5 yl}-2-methyl-propionic acid; Racemic(6-{1-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]ethoxy}-1H-indol-3-yl)-acetic acid; Racemic(6-{1-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-10 1H-indol-3-yl)-acetic acid; $(R)-(5-\{1-[4-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-2-(4-trifluoromethyl-phenyl)-ethylloopadaa-ethyl$ phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid; $(S)-(5-\{1-[4-[2-(2-Chloro-6-fluoro-phenyl]-2-(4-trifluoromethyl-2-(4-t$ phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid; (S)-(5-{1-[4-[2-phenylethyl]-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-15 ethoxy}-indol-1-yl)-acetic acid; ethoxy}-indol-1-yl)-acetic acid; 20 1H-indol-3-yl)-acetic acid; 1H-indol-3-yl)-acetic acid; (S)-(5-{1-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}indol-1-yl)-acetic acid; (R)- $(5-\{1-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy\}$ -25 indol-1-yl)-acetic acid; (R)- $(5-\{1-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy\}$ indol-1-yl)-acetic acid: (R)- $(5-\{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy\}$ -30 indol-1-yl)-acetic acid; (S)-(5-{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-

indol-1-yl)-acetic acid;

- $(S)-(5-\{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-1-methyl-phenyl)-thiazol-4-yl]-1-methyl-phenyl-phe$ ethoxy}-indol-1-yl)-acetic acid; $(R)-(5-\{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-1-methyl-phenyl$ ethoxy}-indol-1-yl)-acetic acid; 5 (R)- $(5-\{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-propoxy}-$ 1H-indol-3-yl)-acetic acid; (S)-(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-propoxy}-1H-indol-3-yl)-acetic acid; (5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-1H-10 indol-3-yl)-acetic acid: (R)-(1-Methyl-5-{2-[5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]propoxy}-1H-indol-3-yl)-acetic acid; propoxy}-1H-indol-3-yl)-acetic acid; (1-Methyl-5-{2-[5-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-15 ethoxy}-1H-indol-3-yl)-acetic acid; $5-\{2-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-yl]-propoxy\}-1H-oxazol-5-yl]-propoxy\}-1H-oxazol-5-yl]-propoxy\}-1H-oxazol-5-yl]-propoxy\}-1H-oxazol-5-yl]-propoxy\}-1H-oxazol-5-yl]-propoxy\}-1H-oxazol-5-yl]-propoxy\}-1H-oxazol-5-yl]-propoxy\}-1H-oxazol-5-yl]-propoxy]-propoxy]-propoxy[-propoxy]-propoxy[-propoxy]-propoxy]-propoxy[-propoxy]-propoxy[$ indole-2-carboxylic acid; $5-\{2-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-yl]-propoxy\}-1-propoxy\}-1-propoxy\}-1-propoxy\}-1-propoxy-1-$ 20 methyl-1H-indole-2-carboxylic acid; N-(2-{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1-yl}-acetyl)-methanesulfonamide; N-(2-{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1-yl}-acetyl)-benzenesulfonamide: $N-[2-(5-\{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy\}-index of the property of the property$ 25 indol-1-yl)-acetyl]-methanesulfonamide; N-[2-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}indol-1-yl)-acetyl]-benzenesulfonamide; and ${\hbox{$1\hbox{-}[4\hbox{-}Isopropyl\hbox{-}2\hbox{-}(4\hbox{-}trifluoromethyl\hbox{-}phenyl)\hbox{-}thiazol\hbox{-}5\hbox{-}ylmethyl]\hbox{-}1$H-indol-leading and the statement of the$ 30 5-yloxy}-acetic acid.
 - 137. The method of Claim 92, wherein the compound is in the S conformation.

30

- 138. The method of Claim 92, wherein the compound is in the R conformation.
- 139. The method of Claim 92, wherein the compound is radiolabeled.

The compound of Claim 1, wherein the compound is selected from the group consisting of:

- {5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1-yl}-acetic acid;
- 10 [5-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-indol-1-yl]-acetic acid;
 - {5-[2-(4-Fluoro-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-acetic acid;
 - {5-[2-(4-Benzyloxy-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-acetic acid;
- 2-Methyl-2-(5-{2-[2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-ethoxy}-indol-1-yl)-propionic acid;
 - {5-[4-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;
 - 2-Methyl-2-(5-{2-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-ethoxy}-indol-1-yl)-propionic acid;
 - {5-[2-(3,5-Bis-trifluoromethyl-phenyl)-4-methyl-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;
 - {5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-indol-1-yl}-acetic acid;
- 25 2-Methyl-2-{5-[4-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-indol-1-yl}-propionic acid;
 - Racemic 2-{5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-indol-1-yl}-propionic acid;
 - {5-[2-(4-Bromo-phenyl)-4-methyl-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;
 - {5-[4-Butyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

2-{5-[4-Butyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1yl}-propionic acid: {5-[4-Phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1yl}-acetic acid: 5 2-{5-[4-(2-Chloro-6-fluoro-phenoxymethyl)-2-(4-trifluoromethyl-phenyl)thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid; Racemic 2-Methyl-2-{5-[4-phenoxymethyl-2-(4-trifluoromethyl-phenyl)thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid; 2-Methyl-2-{5-[4-phenoxymethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-10 ylmethoxy]-indol-1-yl}-propionic acid; 3-{5-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1yl}-propionic acid; 5-{5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1yl}-pentanoic acid; 5-{5-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-15 yl}-pentanoic acid: {5-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1yl}-acetic acid: 2-{5-[4-(2-Chloro-6-fluoro-phenoxymethyl)-2-(4-trifluoromethyl-phenyl)-20 thiazol-5-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid; 5-{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1yl}-pentanoic acid; 5-{5-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}pentanoic acid: 3-{5-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-25 propionic acid: 3-{5-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1yl}-propionic acid: {5-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-30 indol-1-yl}-acetic acid; {5-[4-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-ylmethoxy]-indol-1-yl}acetic acid:

WO 2004/092131

5

20

- (5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;
- {5-[2-(5-Methyl-2-pyridin-4-yl-thiazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid;
- {5-[2-(5-Methyl-2-morpholin-4-yl-thiazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid;
- (5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;
- (5-{2-[5-Methyl-2-(tetrahydro-pyran-4-yl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;
- 10 {5-[2-(2-Butoxy-5-methyl-oxazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid;
 - {5-[2-(5-Methyl-2-pyridin-3-yl-thiazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid;
 - {5-[2-(5-Methyl-2-pyridin-2-yl-thiazol-4-yl)-ethoxy]-indol-1-yl}-acetic acid;
 - (5-{2-[2-(5-Bromo-thiophen-2-yl)-5-methyl-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;
- 15 (5-{2-[2-(3-Bromo-phenyl)-5-methyl-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;
 - (5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;
 - 2-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;
 - (5-{2-[2-(2-Chloro-phenyl)-5-ethyl-thiazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;
 - 2-(5-{2-[2-(2-Chloro-phenyl)-5-ethyl-thiazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;
- 25 (5-{2-[5-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;
 - 2-(5-{2-[5-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;
 - 2-(5-{2-[2-(2-Chloro-phenyl)-5-ethyl-thiazol-4-yl]-ethoxy}-indol-1-yl)-2-methyl-propionic acid;
 - Racemic 2-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;

15

- (5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-acetic acid;
- 2-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-2-methyl-propionic acid;3-(5-{2-[2-(2-Chloro-phenyl)-5-ethyl-thiazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;
- 3-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;
- 2-Methyl-2-(5-{2-[5-propyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;
- 10 Racemic-(5-{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;
 - Racemic-(5-{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;
 - Racemic-(5-{1-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;
 - Racemic-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-1-methyl-ethoxy}-indol-1-yl)-acetic acid;
 - Racemic-(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-propoxy}-indol-1-yl)-acetic acid;
- 20 (5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-propoxy}-indol-1-yl)-acetic acid;
 - (S)-(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-propoxy}-indol-1-yl)-acetic acid;
 - $\label{eq:continuous} \begin{tabular}{ll} (R)-(5-{2-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-propoxy}-indol-1-yl)-acetic acid; \end{tabular}$
 - Racemic-(5-{1-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;
 - Racemic-(5-{1-[4-Ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid;
- 30 {5-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}acetic acid;

20

- Racemic-2-{5-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;
- 2-Methyl-2-{5-[4-propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid:
- 5 Racemic-2-{5-[4-Phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;
 - 2-Methyl-2-{5-[4-phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-propionic acid;
 - {5-[4-tert-Butyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;
 - 2-Methyl-2-[5-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-indol-1-yl]-propionic acid;
 - 2-{5-[2-(4-Trifluoromethyl-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid;
- 2-{5-[2-(4-Fluoro-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid;
 - 2-{5-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid;
 - 2-Methyl-2-(5-{2-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-ethoxy}-indol-1-yl)-propionic acid;
 - 2-(5-{2-[2-(4-Bromo-phenyl)-5-methyl-oxazol-4-yl]-ethoxy}-indol-1-yl)-2-methyl-propionic acid;
 - 2-(5-{2-[2-(5-Bromo-thiophen-2-yl)-5-methyl-oxazol-4-yl]-ethoxy}-indol-1-yl)-2-methyl-propionic acid;
- 25 2-Methyl-2-{5-[2-(5-methyl-2-phenyl-thiazol-4-yl)-ethoxy]-indol-1-yl}propionic acid;
 - {5-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-2-methyl-indol-1-yl}-acetic acid;
 - 2-{5-[2-(3,5-Bis-trifluoromethyl-phenyl)-4-methyl-thiazol-5-ylmethoxy]-indol-1-yl}-2-methyl-propionic acid;
 - {4-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1-yl}-acetic acid;

Racemic-(5-{1-[4-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-2-(4trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid; Racemic-(5-{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-2phenyl-ethoxy}-indol-1-yl)-acetic acid; 5 $Race mic-(5-\{1-[4-Phenethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-1-[4-Phenethyl-2-(4-trifluoromethyl-phenyl-5-yl]-1-[4-Phenethyl-2-(4-trifluoromethyl-phenyl-5-yl]-1-[4-Phenethyl-2-(4-trifluoromethyl-phenyl-5-yl]-1-[4-Phenethyl-2-(4-trifluoromethyl-phenyl-5-yl]-1-[4-Phenethyl-2-(4-trifluoromethyl-p$ ethoxy}-indol-1-yl)-acetic acid; 2-{5-[4-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethoxy]-indol-1yl}-2-methyl-propionic acid; $(R)-(5-\{1-[4-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-2-(4-trifluoromethyl-phenyl)-ethyl-phenyl)-ethyl-phenyl-$ 10 phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid; $(S)-(5-\{1-[4-[2-(2-Chloro-6-fluoro-phenyl)-ethyl]-2-(4-trifluoromethyl-phenyl)-ethyl$ phenyl)-thiazol-5-yl]-ethoxy}-indol-1-yl)-acetic acid; (S)-(5-{1-[4-[2-phenylethyl]-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]ethoxy}-indol-1-yl)-acetic acid; 15 (R)- $(5-\{1-[4-[2-phenylethyl]-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]$ ethoxy}-indol-1-yl)-acetic acid; (S)-(5-{1-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy}indol-1-yl)-acetic acid: $(R)-(5-\{1-[4-Propyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy\}-$ 20 indol-1-yl)-acetic acid; $(R)-(5-\{1-[4-Isopropyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy\}$ indol-1-yl)-acetic acid; $(R)-(5-\{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy\}$ indol-1-yl)-acetic acid; 25 $(S)-(5-\{1-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-ethoxy\}$ indol-1-yl)-acetic acid; (S)-(5-{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-1-methylethoxy}-indol-1-yl)-acetic acid; $(R)-(5-\{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-1-methyl-phenyl$ 30 ethoxy}-indol-1-yl)-acetic acid; N-(2-{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4ylmethoxy]-indol-1-yl}-acetyl)-methanesulfonamide;

 $N-(2-\{5-[5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-indol-1-yl\}-acetyl)-benzenesulfonamide; and \\N-[2-(5-\{2-[5-Ethyl-2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-ethoxy\}-indol-1-yl)-acetyl]-methanesulfonamide.$